A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy

Table 9 Canadian Cardiovascular Society guidelines for CVD prevention and dyslipidemia management: treatment thresholds and targets based on Framingham Risk Score (FRS)[125]

Risk level	Initiate therapy if:	Primary target LDL-C	Alternate target
High	• Consider treatment in all	• ≤2 mmol/L, or	• Apo B ≤0.8 g/L
FRS ≥20%		• ≥50% ↓ in LDL-C	• Non HDL-C ≤2.6 mmol/L
Intermediate	• LDL-C ≥3.5 mmol/L	• ≤2 mmol/L,or	• Apo B ≤0.8 g/L
FRS = 10%-19%	• For LDL-C <3.5 consider if:	• ≥50% ↓ in LDL-C	• Non HDL-C ≤2.6 mmol/L
	→ Apo B ≥1.2 g/L, or
	→ Non-HDL-C ≥4.3 mmol/L
Low	• LDL-C ≥5.0 mmol/L	• ≥50% ↓ in LDL-C
FRS <10%	• Familial hypercholesterolemia

Adapted from Anderson et al., 2013 [125].
FRS Framingham Risk Score, HDL-C high-density lipoprotein cholesterol, LDL-C, low-density lipoprotein cholesterol, apo B apolipoprotein B.

ISSN: 1710-1492